VF
PLX icon

Virtu Financial’s Protalix BioTherapeutics PLX Stock Holding History

Virtu Financial’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,893
Closed -$147K – 2101
2026
Q1 		$147K Buy
+67,893
New +$168K 0.01% 1108
2025
Q4 		– Sell
-16,530
Closed -$37K – 2099
2025
Q3 		$37K Buy
+16,530
New +$26.9K ﹤0.01% 1185
2025
Q1 		– Sell
-34,276
Closed -$64K – 1893
2024
Q4 		$64K Sell
34,276
-9,112
-21% -$12.9K ﹤0.01% 1114
2024
Q3 		$44K Buy
+43,388
New +$45.6K ﹤0.01% 1034
2024
Q2 		– Sell
-157,516
Closed -$198K – 1764
2024
Q1 		$198K Buy
+157,516
New +$235K 0.02% 795
2023
Q4 		– Sell
-11,184
Closed -$19K – 1907
2023
Q3 		$19K Sell
11,184
-924
-8% -$1.66K ﹤0.01% 1024
2023
Q2 		$24K Buy
+12,108
New +$28.8K ﹤0.01% 1235
2022
Q3 		– Sell
-28,816
Closed -$31K – 2118
2022
Q2 		$31K Buy
28,816
+13,617
+90% +$15.9K ﹤0.01% 1245
2022
Q1 		$16K Sell
15,199
-3,172
-17% -$2.91K ﹤0.01% 1324
2021
Q4 		$15K Buy
+18,371
New +$19.2K ﹤0.01% 1541
2021
Q2 		– Sell
-27,744
Closed -$124K – 1951
2021
Q1 		$124K Buy
+27,744
New +$129K 0.01% 1247
2019
Q3 		– Sell
-1,948
Closed -$9K – 1735
2019
Q2 		$9K Sell
1,948
-5,869
-75% -$24.8K ﹤0.01% 1387
2019
Q1 		$34K Sell
7,817
-1,369
-15% -$6.17K ﹤0.01% 1251
2018
Q4 		$29K Buy
9,186
+2,823
+44% +$13.4K ﹤0.01% 1338
2018
Q3 		$46K Buy
6,363
+4,094
+180% +$20.6K ﹤0.01% 1312
2018
Q2 		$10K Buy
+2,269
New +$10.1K ﹤0.01% 1905
2018
Q1 		– Sell
-3,599
Closed -$24K – 2442
2017
Q4 		$24K Buy
3,599
+653
+22% +$4.41K ﹤0.01% 2197
2017
Q3 		$17K Buy
+2,946
New +$18.9K ﹤0.01% 2370

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Virtu Financial's PLX Position: Q2 2026 in Review

Virtu Financial sold out of Protalix BioTherapeutics (PLX) in Q2 2026, closing a stake of 67,893 shares — an estimated $147K sold.

Virtu Financial first reported a position in PLX in Q3 2017 and held it in 18 quarters. The position peaked at $198K in Q1 2024. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Virtu Financial reported no remaining Protalix BioTherapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 67,893 Protalix BioTherapeutics shares in Q2 2026, an estimated $147K.
  • Virtu Financial first reported a position in Protalix BioTherapeutics in Q3 2017 and held it in 18 quarters.
  • Virtu Financial's Protalix BioTherapeutics position peaked at $198K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.